• Figure 1.

    Suggested algorithm for fracture risk screening and initiation of anti-fracture strategies in patients with CKD

  • Figure 2.

    Suggested algorithm for management of fractures

  • 1.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 76 (Suppl 113): S1130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Ketteler M, et al. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. Kidney Int Suppl 2017; 7[Suppl 1]:159.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol 2018; 13:962969.

  • 4.

    Pimentel A, et al. Fractures in patients with CKD—diagnosis, treatment, and prevention: A review by members of the European Calcified Tissue Society and the European Renal Association—European Dialysis and Transplant Association. Kidney Int 2017; 92:13431355.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Isakova T, et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol 2018; 29:579590.

  • 6.

    Ross AC, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011; 96:5358.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Levin A, et al. Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD. Clin J Am Soc Nephrol 2017; 12:14471460.

  • 8.

    Kumar V, et al. A randomized trial of vitamin D supplementation on vascular function in CKD. J Am Soc Nephrol 2017; 28:31003108.

  • 9.

    Courbebaisse M, et al. Non-skeletal and skeletal effects of high doses versus minimum recommended intake of vitamin D3 in renal transplant recipients in a prospective, multicenter, double-blind, randomized study. Late Breaking Clinical Trial Abstract, ERA-EDTA Congress 2019, Budapest.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Sprague SM, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 2016; 44:316325.

  • 11.

    Strugnell SA, et al. Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease. Am J Nephrol 2019; 49:284293.

  • 12.

    Cozzolino M, Ketteler M. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert Opin Pharmacother. 2019; 20: 2081-2093.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Scragg R, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: A randomized clinical trial. JAMA Cardiol 2017; 2:608616.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Scragg R, et al. Monthly high-dose vitamin D supplementation and cancer risk: A post hoc analysis of the vitamin D assessment randomized clinical trial. JAMA Oncol 2018; 4:e182178.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380:3344.

  • 16.

    de Boer IH, Zelnick LR, Ruzinski J, et al. Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: A randomized clinical Trial. JAMA. 2019; doi: 10.1001/jama.2019.17380.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Chronic Kidney Disease–Mineral and Bone Disorder: Personal Perspective after the 2017 KDIGO CKD-MBD Guideline Update

Markus Ketteler Markus Ketteler, MD, FERA, is the head of the Department of General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany.

Search for other papers by Markus Ketteler in
Current site
Google Scholar
PubMed
Close
Restricted access
Save